BioCentury
ARTICLE | Company News

BMY, Otsuka submit aripiprazole MAA

December 17, 2001 8:00 AM UTC

Bristol-Myers (BMY) and partner Otsuka (Tokyo, Japan) submitted an MAA to the EMEA for aripiprazole, a once daily small molecule partial agonist of dopamine D2 receptors, to treat schizophrenia. The p...